Abstract
Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax ® in vaccinia-naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax ® challenge at 3 months. Two or more doses of MVA prior to Dryvax ® reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax ® vaccinia-specific CD8+ T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax ® vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
